retatrutide type 2 diabetes phase 2 trial 2024 The Effect of on Kidney Parameters in Participants With Mellitus and/or Obesity A new weight-loss drug called – retatrutide type 2 diabetes phase

Several practical factors may explain fatigue during GLP-1 therapy: Reduced food intake due to appetite suppression can lead to lower energy consumption Gastrointestinal side effects like nausea can be physically draining Adaptation to metabolic changes as your body adjusts to the medication For people with diabetes who take insulin or sulfonylureas (like gliclazide) alongside GLP-1 medications, low blood glucose (hypoglycaemia) may cause fatigue

Safety risks primarily arise from unverified sources and non-compliant injectable routes

This sounds a lot like what prescription drugs like semaglutide (sold as Ozempic or Wegovy) do

Muscle Loss with Rapid Weight Loss : Losing weight too quickly on semaglutide can lead to muscle breakdown, which may slow metabolism over time

4G, with significant pathways including Arachidonic acid metabolism (P = 0.0009), Biosynthesis of unsaturated fatty acids (P = 0.0010), Linoleic acid metabolism (P = 0.0335), and Ferroptosis (P = 0.0398)